MOUNTAIN VIEW, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences...
Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1Filing based on four Phase 3...
Presentations collectively highlight pilavapadin’s potential to improve pain management care for patients with diabetic peripheral neuropathic pain (DPNP) Breadth of...
MORRISTOWN, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., today...
RUTHERFORD, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company...
Allocetra™ demonstrated statistically significant and clinically meaningful improvements in pain and function in Phase IIa trial in primary osteoarthritis patients Six-month...
Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor.1 Filing based on four Phase 3...
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing...
SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing...
Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications...
New Positive Preclinical Data Shows Succesful Drug Distribution to Liver, Peritoneum, and Lung with Measurable Reductions in Tumor Burden at...
The study represents the first successful prospective genetic biomarker-guided drug trial in psychiatrySAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) --...
Marks a significant milestone in ongoing collaboration between RadioMedix and Vect-Horus to advance innovative Theranostic radiopharmaceuticals to address unmet needs...
Scientific Advisory Board member, Dr. Noriyuki Kasahara, appointed Chief Scientific Officer of GenVivo, to accelerate the achievement of major clinical...
Safety endpoint met, with encouraging signs of efficacy in trial with 23 patients suffering from intracerebral hemorrhage (ICH)Findings suggest BIOX-101...
NOTTINGHAM, United Kingdom, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope®...
- Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against infection in...
Vancouver, British Columbia--(Newsfile Corp. - September 11, 2025) - Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzdTM...
Hemogenyx Pharmaceuticals Invited to Participate at DCNY Summit LONDON, UK / ACCESS Newswire / September 11, 2025 / Hemogenyx Pharmaceuticals...
Calgary, Alberta--(Newsfile Corp. - September 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Company"), the leading autologous...